Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS-Reference-Cited by-同舟云学术

Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS

Published:2024-04 Issue: Volume:201 Page:113923
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Chaix Jordane^ORCID,Schleiermacher Gudrun,Corradini Nadège,André Nicolas^ORCID,Thebaud Estelle,Gambart Marion,Defachelles Anne-Sophie,Entz-Werle Natacha,Chastagner Pascal,De Carli Émilie,Ducassou Stéphane,Landman-Parker Judith,Adam-de-Beaumais Tiphaine^ORCID,Larive Alicia,Michiels Stefan,Vassal Gilles,Valteau-Couanet Dominique,Geoerger Birgit^ORCID,Berlanga Pablo

Publisher

Elsevier BV

Reference32 articles.

1. Neuroblastoma;Maris;Lancet,2007

2. Neuroblastoma;Matthay;Nat Rev Dis Prim,2016

3. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the international neuroblastoma risk group project;London;J Clin Oncol,2011

4. BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.

5. Bevacizumab, Irinotecan, or topotecan added to temozolomide for children with relapsed and refractory neuroblastoma: results of the ITCC-SIOPEN BEACON-neuroblastoma trial;Moreno;J Clin Oncol,2024

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART;European Journal of Cancer;2024-09